A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Scientists have created the most detailed map to date of the human hypothalamus, a crucial brain region that regulates body ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Here’s what to expect when metformin needs to be replaced. Metformin is an oral medication used to treat type 2 diabetes. It belongs to a class of drugs called biguanides. Diabetes occurs when your ...

The key is balancing these benefits with the safety concerns of following this eating plan when taking diabetes medications. IF is a type of eating plan that involves limiting the time period when you ...

Medically, Gestational (jes-TAY-shun-ul) Diabetes Mellitus (GDM ... with different values with small variations as shown in the chart below. You should initially consult with your obstetrician ...

Last fall, the federal pharmacare legislation was passed, laying the groundwork for Ottawa to begin covering the cost of contraceptive and diabetes drugs and devices and Holland is still working ...

but some drugs used to treat diabetes can make your cells more open or sensitive to insulin. They’re sometimes called insulin sensitizers. Two types, or classes, of diabetes drugs can improve ...

While this option may be less expensive and seems convenient, it’s best to consult a doctor about dosage if you use it, says Joshua J. Neumiller, CDCES, PharmD, the president elect of ...

Drugs for diabetes, HIV, cancer saw price hikes, among others. For years a 10% annual price hike was fairly normal, but they've started coming down in recent years. This year's median price hike ...

the GLP-1 class drug behind the brand-name weight-loss and diabetes drugs Wegovy and Ozempic, made by Novo Nordisk. That would be bad news for Lilly, which makes competing GLP-1 drugs Zepbound and ...